Future research will develop allosteric ligands targeting phosphorylation motifs in the glucocorticoid receptor as more specific alternative to orthosteric ligands for the treatment of obesity-related brain comorbidities. This evidence concerns the gene NR3C1 and obesity due to melanocortin 4 receptor deficiency.